Download PDF
Hamostaseologie 2011; 31(01): 07-12
DOI: 10.5482/ha-1144
Übersichtsarbeit
Schattauer GmbH

Bewertung des Rezidivthrombose-risikos venöser Thromboembolien

Risk assessment of recurrence of venous thromboembolism
E. Lindhoff-Last
1   Schwerpunkt Angiologie/Hämostaseologie, Med. Klinik III, Klinikum der J. W. Goethe-Universität Frankfurt am Main
› Author Affiliations
Further Information

Publication History



09 December 2010

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Recurrent venous thromboembolism is associated with increased mortality in 5–9% of the patients. On the other hand prolonged anticoagulation can increase the bleeding risk which can also be responsible for an increased mortality. Therefore, it is necessary to validate the recurrence risk of venous thromboembolism on an individual basis.

In this review the most relevant risk factors for recurrent venous thromboembolism are analyzed. Spontaneous thrombosis is associated with significantly increased recurrence rates in comparison to risk associated venous thrombosis. In addition, a positive D-dimer result after stop of anticoagulation, an increased amount of residual thrombus in proximal veins analyzed by compression sonography, a proximal localization of thrombosis, symptomatic pulmonary embolism and male sex are clinically relevant risk factors for increased recurrence rates. While mild thrombophilic defects like heterozygous factor V Leiden mutation are not associated with a clinically relevant recurrence risk, inherited inhibitor deficiencies and the anti-phospholipid-syndrome are known to be responsible for an increased recurrence rate of venous thromboembolism. A new recurrence risk-score (RR-Score) for individual judgement of patients with a first spontaneous venous thrombosis is introduced.

Zusammenfassung

Venöse Rezidivthrombosen können in 5–9% der Patienten tödlich sein. Auf der anderen Seite kann eine unnötig lange Fortsetzung der Antikoagulation zu einem deutlich erhöhten Blutungsrisiko für schwere Blutungen führen, das ebenfalls mit einer erhöhten Mortalität assoziiert sein kann. Daher ist eine individuelle Bewertung des Rezidivthromboserisikos von größter klinischer Relevanz.

In diesem Review sollen daher die wesentlichen Determinanten für ein erhöhtes Rezidivrisiko bewertet werden. Das Rezidivrisiko ist bei Auftreten spontaner venöser Thrombosen wesentlich höher als bei Risiko-assoziierten Thrombosen.Weitere klinisch relevante Determinanten sind ein positiver D-Dimertest nach Beendigung der Antikoagulation, die Restthrombuslast im Bereich proximaler Venen im Kompressionsultraschall, eine proximale Lokalisation der Thrombose, das Auftreten einer klinisch symptomatischen Lungenembolie und das männliche Geschlecht. Milde thrombophile Neigungen wie z. B. die heterozygote Faktor-V-Leiden-Mutation spielen keine wesentliche Rolle für das Rezidivthromboserisiko, wogegen angeborene Inhibitormängel und das Antiphospholipid-Syndrom mit einem deutlich erhöhten Rezidivrisiko assoziiert sind. Abschließend wird ein neuer Rezidiv-Risiko-Score (RR-Score) zur individuellen Bewertung des Rezidivrisikos bei Patienten mit spontaner Erstthrombose vorgestellt.

Keywords

Venous thromboembolism

Schlüsselwörter

Venöse Rezidivthrombose
 

  • Literatur

  • 1 Douketis JD, Gu CS, Schuman S. et al. The risk of fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 14: 766-774.
    PubMedGoogle Scholar
  • 2 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism – a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
    CrossrefPubMedGoogle Scholar
  • 3 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidencebased clinical practice guidelines. Chest 2008; 133: 454S-545S.
    CrossrefPubMedGoogle Scholar
  • 4 Hach-Wunderle V, Blättler W, Gerlach H. et al. Interdisziplinäre S2-Leitlinie: Diagnostik und Therapie der Bein- und Beckenvenentrhombose und der Lungenembolie. VASA 2010; 66 (Suppl. 66) 1-39.
    PubMedGoogle Scholar
  • 5 Lijering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis – current understanding from an epidemiological point of view. BJH 2010; 149: 824-833.
    CrossrefPubMedGoogle Scholar
  • 6 Schulman S, Rebecca J, Beyth RJ. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians, Evidence-based clinical practice guidelines. Chest 2008; 133 (Suppl. 06) 257S-298S.
    CrossrefPubMedGoogle Scholar
  • 7 Prandoni P, Lensing AWA, Cogo A. et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 8 Pini M, Aiello S. Manotti et al. Low molecular weight heparin versus warfarin in the prevention of recurrence after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007; 92: 199-205.
    CrossrefPubMedGoogle Scholar
  • 10 Eichinger S, Minar E, Bialonczyk C. et al. D-dimer Tab. 2 Vorschlag für die Anwendung des Rezidivrisiko-Scores (RR-Score) bei spontaner, venöser Erstthrombose im klinischen Alltag (bisher nicht in prospektiven Studien klinisch validiert) levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-1074.
    CrossrefPubMedGoogle Scholar
  • 11 Palareti G, Legnani C, Cosmi B. et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Palareti G, Legnani C, Cosmi B. et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318.
    CrossrefPubMedGoogle Scholar
  • 13 Palareti G, Cosmi B, Legnani C. et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
    CrossrefPubMedGoogle Scholar
  • 14 Bruinstroop E, Klok FA, Van de Ree MA. et al. Elevated D-dimer levels predict recurrence in patients of idiopathic venous thromboembolism. A metaanalysis. J Thromb Haemost 2009; 07: 611-618.
    CrossrefPubMedGoogle Scholar
  • 15 Cosmi B, Legnani C, Tosetto A. et al. PROLONG Investigators. Usefulness of repeated D-dimer testing after stopping anticoagulaition for a first episode of unprovoked venous thromboembolis. Blood 2010; 115: 481-488.
    CrossrefPubMedGoogle Scholar
  • 16 Young L, Ockelford P, Milne D. et al. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 04: 1919-1924.
    CrossrefPubMedGoogle Scholar
  • 17 Siragusa S, Malato A, Anastasio R. et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis. The duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 2008; 112: 511-515.
    CrossrefPubMedGoogle Scholar
  • 18 Prandoni P, Prins MH, Lensing AWA. et al. AESOPUS Investigators. Residual thrombosis on ultrasound to guide the duration of anticoagulation in patients with deep venous thrombosis. Ann Intern Med 2009; 150: 577-585.
    CrossrefPubMedGoogle Scholar
  • 19 Anderson JFA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107: 9-16.
    CrossrefPubMedGoogle Scholar
  • 20 Akl EA, Barba M, Rohilla S. et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane database Syst Rev 2008; CD006650.
    PubMedGoogle Scholar
  • 21 Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210 mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
    CrossrefPubMedGoogle Scholar
  • 22 Lijfering WM, Middeldorp S, Veeger NJ. et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121: 1706-1712.
    CrossrefPubMedGoogle Scholar
  • 23 Taliani MR, Becattini C, Agnelli G. et al. WODIT Investigators. Duration of anticoagulant treatment and recurrence of venous thromboembolismin patients with and without thrombophilic abnormalities. Thromb Haemost 2009; 101: 596-598.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Cohn D, Vansenne F, de Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database of systematic reviews 2009; 01: CD007069.
    PubMedGoogle Scholar
  • 25 Brouwer JL, Lijfering WM, Ten Kate MK. et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C and antithrombin. Thromb Haemost 2009; 101: 93-99.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Schulman S, Lindmarker P, Homstrom M. et al. Postthrombotic syndrome, recurrence and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 04: 734-742.
    CrossrefPubMedGoogle Scholar
  • 27 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-338.
    CrossrefPubMedGoogle Scholar
  • 28 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphosp-holipid syndrome. J Thromb Haemost 2010; 08: 237-242.
    CrossrefPubMedGoogle Scholar
  • 29 Palla A, Ribas C, Rossi G. et al. The clinical course of pulmonary embolism patients anticoagulated for 1 year: results of a prospective observational, cohort study. J Thromb Haemost 2010; 08: 69-74.
    PubMedGoogle Scholar
  • 30 Baglin T, Douketis J, Tosetto A. et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis. J Thromb Haemost. 2010 in press.
    PubMedGoogle Scholar
  • 31 Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004; 02: 2152-2155.
    CrossrefPubMedGoogle Scholar
  • 32 Kyrle PA, Minar E, Bialonczyk C. et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-2563.
    CrossrefPubMedGoogle Scholar
  • 33 McRae S, Tran H, Schulman S. et al. Effect of patient`s sex on risk of recurrent venous thromboembolism: a metaanalysis. Lancet 2006; 368: 371-378.
    CrossrefPubMedGoogle Scholar
  • 34 Cosmi B, Legnani C, Tosetto A. et al. PROLONG investigators. Sex, age and normal pot-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost 2010; 08: 1933-1942.
    CrossrefPubMedGoogle Scholar
  • 35 Christiansen SC, Lijfering WM, Helmerhorst FM. et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 2010; 08: 2159-2168.
    CrossrefPubMedGoogle Scholar
  • 36 Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism The Vienna prediction model. Circulation 2010; 121: 1630-1636.
    CrossrefPubMedGoogle Scholar